These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 27180657)

  • 21. Staggered and tapered antibiotic withdrawal with administration of kefir for recurrent Clostridium difficile infection.
    Bakken JS
    Clin Infect Dis; 2014 Sep; 59(6):858-61. PubMed ID: 24917658
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial.
    Hickson M; D'Souza AL; Muthu N; Rogers TR; Want S; Rajkumar C; Bulpitt CJ
    BMJ; 2007 Jul; 335(7610):80. PubMed ID: 17604300
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review article: the use of biotherapeutic agents in the prevention and treatment of gastrointestinal disease.
    Lewis SJ; Freedman AR
    Aliment Pharmacol Ther; 1998 Sep; 12(9):807-22. PubMed ID: 9768523
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clostridium difficile: improving the prevention paradigm in healthcare settings.
    Vassallo A; Tran MC; Goldstein EJ
    Expert Rev Anti Infect Ther; 2014 Sep; 12(9):1087-102. PubMed ID: 25109301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel approaches to treating Clostridium difficile-associated colitis.
    Padua D; Pothoulakis C
    Expert Rev Gastroenterol Hepatol; 2016; 10(2):193-204. PubMed ID: 26643655
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies.
    Hudson LE; Anderson SE; Corbett AH; Lamb TJ
    Clin Microbiol Rev; 2017 Jan; 30(1):191-231. PubMed ID: 27856521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Harnessing nature for treating infectious and autoimmune diseases: good and bad bacteria].
    Israeli E; Shoenfeld Y
    Harefuah; 2013 Apr; 152(4):188-9, 249. PubMed ID: 23844515
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Probiotics for the prevention and treatment of Clostridium difficile in older patients.
    Islam J; Cohen J; Rajkumar C; Llewelyn MJ
    Age Ageing; 2012 Nov; 41(6):706-11. PubMed ID: 22718155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural and functional changes within the gut microbiota and susceptibility to Clostridium difficile infection.
    Ross CL; Spinler JK; Savidge TC
    Anaerobe; 2016 Oct; 41():37-43. PubMed ID: 27180006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic evaluation of fecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection in Australia.
    Merlo G; Graves N; Brain D; Connelly LB
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1927-1932. PubMed ID: 27043242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Intestinal microbiota in individualized therapies].
    Witte T; Pieper DH; Heidrich B
    Internist (Berl); 2017 Jul; 58(7):682-686. PubMed ID: 28540475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Breakthroughs in the treatment and prevention of Clostridium difficile infection.
    Kociolek LK; Gerding DN
    Nat Rev Gastroenterol Hepatol; 2016 Mar; 13(3):150-60. PubMed ID: 26860266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibiotic-associated diarrhea and pseudomembranous colitis: are they less common with poorly absorbed antimicrobials?
    Surawicz CM
    Chemotherapy; 2005; 51 Suppl 1():81-9. PubMed ID: 15855751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alternative therapies for Clostridium difficile infections.
    Venuto C; Butler M; Ashley ED; Brown J
    Pharmacotherapy; 2010 Dec; 30(12):1266-78. PubMed ID: 21114394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Saccharomyces boulardii for the prevention of hospital onset Clostridium difficile infection.
    Flatley EA; Wilde AM; Nailor MD
    J Gastrointestin Liver Dis; 2015 Mar; 24(1):21-4. PubMed ID: 25822430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of the microbiome, probiotics, and 'dysbiosis therapy' in critical illness.
    Wischmeyer PE; McDonald D; Knight R
    Curr Opin Crit Care; 2016 Aug; 22(4):347-53. PubMed ID: 27327243
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of microbial derived secondary bile acids on colonization resistance against Clostridium difficile in the gastrointestinal tract.
    Winston JA; Theriot CM
    Anaerobe; 2016 Oct; 41():44-50. PubMed ID: 27163871
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Probiotics for the antibiotics associated diarrhea and for Clostridium difficile infection.].
    Capurso L; Koch M
    Recenti Prog Med; 2021 Jan; 112(1):27-41. PubMed ID: 33576349
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of alternative or adjuvant pharmacologic treatment strategies in the prevention and treatment of Clostridium difficile infection.
    Musgrave CR; Bookstaver PB; Sutton SS; Miller AD
    Int J Infect Dis; 2011 Jul; 15(7):e438-48. PubMed ID: 21596604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Probiotics for antibiotic-associated diarrhea: do we have a verdict?
    Issa I; Moucari R
    World J Gastroenterol; 2014 Dec; 20(47):17788-95. PubMed ID: 25548477
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.